Click here to get full coverage on KZR Embarks on Strategic Alternatives and Restructuring Plan - GuruFocus

KZR Embarks on Strategic Alternatives and Restructuring Plan  GuruFocus

KZR Embarks on Strategic Alternatives and Restructuring Plan - GuruFocus

Click here to get full coverage on All You Need to Know About Kezar Life Sciences (KZR) Rating Upgrade to Buy - Yahoo Finance

All You Need to Know About Kezar Life Sciences (KZR) Rating Upgrade to Buy  Yahoo Finance

All You Need to Know About Kezar Life Sciences (KZR) Rating Upgrade to Buy - Yahoo Finance

Click here to get full coverage on Kezar (NASDAQ: KZR) posts 36% remission in AIH at steroid doses ≤5 mg/day at AASLD - Stock Titan

Kezar (NASDAQ: KZR) posts 36% remission in AIH at steroid doses ≤5 mg/day at AASLD  Stock Titan

Kezar (NASDAQ: KZR) posts 36% remission in AIH at steroid doses ≤5 mg/day at AASLD - Stock Titan

Click here to get full coverage on Kezar Life Sciences Reports Third Quarter 2025 Financial Results - Business Wire

Kezar Life Sciences Reports Third Quarter 2025 Financial Results  Business Wire

Kezar Life Sciences Reports Third Quarter 2025 Financial Results - Business Wire

Click here to get full coverage on Wells Fargo Maintains Kezar Life Sciences (KZR) Equal-Weight Recommendation - Nasdaq

Wells Fargo Maintains Kezar Life Sciences (KZR) Equal-Weight Recommendation  Nasdaq

Wells Fargo Maintains Kezar Life Sciences (KZR) Equal-Weight Recommendation - Nasdaq

Click here to get full coverage on Kezar Life Sciences Announces Major Workforce Reduction - MSN

Kezar Life Sciences Announces Major Workforce Reduction  MSN

Kezar Life Sciences Announces Major Workforce Reduction - MSN

Click here to get full coverage on Kezar Launches Review After FDA Blocks Liver Drug Plans - Kezar Life Sciences (NASDAQ:KZR) - Benzinga

Kezar Launches Review After FDA Blocks Liver Drug Plans - Kezar Life Sciences (NASDAQ:KZR)  Benzinga

Kezar Launches Review After FDA Blocks Liver Drug Plans - Kezar Life Sciences (NASDAQ:KZR) - Benzinga

Click here to get full coverage on William Blair downgrades Kezar Life Sciences (KZR) to a Hold - The Globe and Mail

William Blair downgrades Kezar Life Sciences (KZR) to a Hold  The Globe and Mail

William Blair downgrades Kezar Life Sciences (KZR) to a Hold - The Globe and Mail

Click here to get full coverage on Kezar Life Sciences Stock Hit With Downgrades And Price Target Cuts: Retail Keeps Hopes Alive - Stocktwits

Kezar Life Sciences Stock Hit With Downgrades And Price Target Cuts: Retail Keeps Hopes Alive  Stocktwits

Kezar Life Sciences Stock Hit With Downgrades And Price Target Cuts: Retail Keeps Hopes Alive - Stocktwits

Click here to get full coverage on Kezar Life Sciences stock climbs as company seeks strategic alternatives - Investing.com

Kezar Life Sciences stock climbs as company seeks strategic alternatives  Investing.com

Kezar Life Sciences stock climbs as company seeks strategic alternatives - Investing.com

Click here to get full coverage on Wells Fargo Lowers Price Target for KZR Amid Maintained Equal-We - GuruFocus

Wells Fargo Lowers Price Target for KZR Amid Maintained Equal-We  GuruFocus

Wells Fargo Lowers Price Target for KZR Amid Maintained Equal-We - GuruFocus

Click here to get full coverage on Kezar Life Sciences Announces Regulatory Update on Zetomipzomib Program in Autoimmune Hepatitis and Plans to Explore Strategic Alternatives - Business Wire

Kezar Life Sciences Announces Regulatory Update on Zetomipzomib Program in Autoimmune Hepatitis and Plans to Explore Strategic Alternatives  Business Wire

Kezar Life Sciences Announces Regulatory Update on Zetomipzomib Program in Autoimmune Hepatitis and Plans to Explore Strategic Alternatives - Business Wire

Click here to get full coverage on Kezar Life Sciences (KZR) Upgraded to Buy: What Does It Mean for the Stock? - Nasdaq

Kezar Life Sciences (KZR) Upgraded to Buy: What Does It Mean for the Stock?  Nasdaq

Kezar Life Sciences (KZR) Upgraded to Buy: What Does It Mean for the Stock? - Nasdaq

Click here to get full coverage on Jefferies Downgrades Kezar Life Sciences (KZR) and Lowers Price Target | KZR Stock News - GuruFocus

Jefferies Downgrades Kezar Life Sciences (KZR) and Lowers Price Target | KZR Stock News  GuruFocus

Jefferies Downgrades Kezar Life Sciences (KZR) and Lowers Price Target | KZR Stock News - GuruFocus

Click here to get full coverage on Kezar Life Sciences to Participate in Two Upcoming Investor Conferences - Business Wire

Kezar Life Sciences to Participate in Two Upcoming Investor Conferences  Business Wire

Kezar Life Sciences to Participate in Two Upcoming Investor Conferences - Business Wire

Click here to get full coverage on KZR Explores Strategic Options Amid Regulatory Hurdles - GuruFocus

KZR Explores Strategic Options Amid Regulatory Hurdles  GuruFocus

KZR Explores Strategic Options Amid Regulatory Hurdles - GuruFocus

Click here to get full coverage on KZR: William Blair Downgrades Kezar Life Sciences Rating | KZR S - GuruFocus

KZR: William Blair Downgrades Kezar Life Sciences Rating | KZR S  GuruFocus

KZR: William Blair Downgrades Kezar Life Sciences Rating | KZR S - GuruFocus

Click here to get full coverage on Kezar Life Sciences Reports First Quarter 2025 Financial Results and Provides Business Update - Business Wire

Kezar Life Sciences Reports First Quarter 2025 Financial Results and Provides Business Update  Business Wire

Kezar Life Sciences Reports First Quarter 2025 Financial Results and Provides Business Update - Business Wire

Click here to get full coverage on Kezar Life Sciences Inc expected to post a loss of $2.08 a share - Earnings Preview - TradingView

Kezar Life Sciences Inc expected to post a loss of $2.08 a share - Earnings Preview  TradingView

Kezar Life Sciences Inc expected to post a loss of $2.08 a share - Earnings Preview - TradingView

Click here to get full coverage on Kezar Life Sciences Reins In Losses With Major Cost Cuts - Finimize

Kezar Life Sciences Reins In Losses With Major Cost Cuts  Finimize

Kezar Life Sciences Reins In Losses With Major Cost Cuts - Finimize

Click here to get full coverage on Kezar Life Sciences to Participate in the Jefferies Global Healthcare Conference - Business Wire

Kezar Life Sciences to Participate in the Jefferies Global Healthcare Conference  Business Wire

Kezar Life Sciences to Participate in the Jefferies Global Healthcare Conference - Business Wire

Click here to get full coverage on Kezar Life Sciences seeks strategic alternatives after FDA setback - Investing.com

Kezar Life Sciences seeks strategic alternatives after FDA setback  Investing.com

Kezar Life Sciences seeks strategic alternatives after FDA setback - Investing.com

Click here to get full coverage on William Blair downgrades Kezar Life Sciences stock rating on FDA setback - Investing.com

William Blair downgrades Kezar Life Sciences stock rating on FDA setback  Investing.com

William Blair downgrades Kezar Life Sciences stock rating on FDA setback - Investing.com

Click here to get full coverage on Kezar Life Sciences Reports Second Quarter 2025 Financial Results and Provides Business Update - Business Wire

Kezar Life Sciences Reports Second Quarter 2025 Financial Results and Provides Business Update  Business Wire

Kezar Life Sciences Reports Second Quarter 2025 Financial Results and Provides Business Update - Business Wire

Click here to get full coverage on Australia's Kalamazoo Resources rises on Xanadu gold project acquisition - TradingView

Australia's Kalamazoo Resources rises on Xanadu gold project acquisition  TradingView

Australia's Kalamazoo Resources rises on Xanadu gold project acquisition - TradingView

Click here to get full coverage on Kezar Life Sciences Announces FDA Has Lifted Partial Clinical Hold on PORTOLA Phase 2a Trial Evaluating Zetomipzomib for the Treatment of Patients with Autoimmune Hepatitis - Business Wire

Kezar Life Sciences Announces FDA Has Lifted Partial Clinical Hold on PORTOLA Phase 2a Trial Evaluating Zetomipzomib for the Treatment of Patients with Autoimmune Hepatitis  Business Wire

Kezar Life Sciences Announces FDA Has Lifted Partial Clinical Hold on PORTOLA Phase 2a Trial Evaluating Zetomipzomib for the Treatment of Patients with Autoimmune Hepatitis - Business Wire

Click here to get full coverage on TD Cowen Maintains Kezar Life Sciences(KZR.US) With Buy Rating - 富途牛牛

TD Cowen Maintains Kezar Life Sciences(KZR.US) With Buy Rating  富途牛牛

TD Cowen Maintains Kezar Life Sciences(KZR.US) With Buy Rating - 富途牛牛

Click here to get full coverage on Kezar Life Sciences Faces FDA Challenges in Drug Program - TipRanks

Kezar Life Sciences Faces FDA Challenges in Drug Program  TipRanks

Kezar Life Sciences Faces FDA Challenges in Drug Program - TipRanks

Click here to get full coverage on Kezar Life Sciences (KZR) Stock Forecast and Price Target 2025 - MarketBeat

Kezar Life Sciences (KZR) Stock Forecast and Price Target 2025  MarketBeat

Kezar Life Sciences (KZR) Stock Forecast and Price Target 2025 - MarketBeat

Click here to get full coverage on Kezar drops solid tumor drug that has yet to prove worth in phase 1 - Fierce Biotech

Kezar drops solid tumor drug that has yet to prove worth in phase 1  Fierce Biotech

Kezar drops solid tumor drug that has yet to prove worth in phase 1 - Fierce Biotech

Click here to get full coverage on Glancy Prongay & Murray LLP Announces Investigation of Kezar Life Sciences, Inc. (KZR) - Business Wire

Glancy Prongay & Murray LLP Announces Investigation of Kezar Life Sciences, Inc. (KZR)  Business Wire

Glancy Prongay & Murray LLP Announces Investigation of Kezar Life Sciences, Inc. (KZR) - Business Wire

Click here to get full coverage on Signal peptide mimicry primes Sec61 for client-selective inhibition - Nature

Signal peptide mimicry primes Sec61 for client-selective inhibition  Nature

Signal peptide mimicry primes Sec61 for client-selective inhibition - Nature

Click here to get full coverage on Kezar Life Sciences Announces 1-for-10 Reverse Stock Split - Business Wire

Kezar Life Sciences Announces 1-for-10 Reverse Stock Split  Business Wire

Kezar Life Sciences Announces 1-for-10 Reverse Stock Split - Business Wire

Click here to get full coverage on Penny Stock Kezar Life Sciences Rejects Acquisition Deal From Concentra Biosciences At $1.10/Share, Shelves Mid-Stage Lupus Nephritis Study - Yahoo Finance

Penny Stock Kezar Life Sciences Rejects Acquisition Deal From Concentra Biosciences At $1.10/Share, Shelves Mid-Stage Lupus Nephritis Study  Yahoo Finance

Penny Stock Kezar Life Sciences Rejects Acquisition Deal From Concentra Biosciences At $1.10/Share, Shelves Mid-Stage Lupus Nephritis Study - Yahoo Finance

Click here to get full coverage on Kezar stalls solid tumour trial to focus on autoimmune disease candidate - Pharmaceutical Technology

Kezar stalls solid tumour trial to focus on autoimmune disease candidate  Pharmaceutical Technology

Kezar stalls solid tumour trial to focus on autoimmune disease candidate - Pharmaceutical Technology

Click here to get full coverage on KZR Stock Price and Chart — NASDAQ:KZR - TradingView

KZR Stock Price and Chart — NASDAQ:KZR  TradingView

KZR Stock Price and Chart — NASDAQ:KZR - TradingView

Click here to get full coverage on Kalamazoo grants De Grey extension for Ashburton deal - Mining.com.au

Kalamazoo grants De Grey extension for Ashburton deal  Mining.com.au

Kalamazoo grants De Grey extension for Ashburton deal - Mining.com.au

Click here to get full coverage on Kezar struck again with second FDA hold - Clinical Trials Arena

Kezar struck again with second FDA hold  Clinical Trials Arena

Kezar struck again with second FDA hold - Clinical Trials Arena

Click here to get full coverage on Setback for Kezar Life Sciences’ Lupus candidate zetomipzomib - The Pharma Letter

Setback for Kezar Life Sciences’ Lupus candidate zetomipzomib  The Pharma Letter

Setback for Kezar Life Sciences’ Lupus candidate zetomipzomib - The Pharma Letter

Click here to get full coverage on Kezar Life Sciences announces 1-for-10 reverse stock split - Nasdaq

Kezar Life Sciences announces 1-for-10 reverse stock split  Nasdaq

Kezar Life Sciences announces 1-for-10 reverse stock split - Nasdaq

Click here to get full coverage on KZR stock falls after R&D event as William Blair downgrades (NASDAQ:KZR) - Seeking Alpha

KZR stock falls after R&D event as William Blair downgrades (NASDAQ:KZR)  Seeking Alpha

KZR stock falls after R&D event as William Blair downgrades (NASDAQ:KZR) - Seeking Alpha

Click here to get full coverage on SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Kezar Life Sciences, Inc. (NASDAQ: KZR) - PR Newswire

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Kezar Life Sciences, Inc. (NASDAQ: KZR)  PR Newswire

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Kezar Life Sciences, Inc. (NASDAQ: KZR) - PR Newswire

Click here to get full coverage on Kent kzr online - The Namibian -

Kent kzr online - The Namibian -

Click here to get full coverage on Kezar Life Sciences to Participate in Three Upcoming Investor Conferences - Business Wire

Kezar Life Sciences to Participate in Three Upcoming Investor Conferences  Business Wire

Kezar Life Sciences to Participate in Three Upcoming Investor Conferences - Business Wire

Click here to get full coverage on 3 Top Penny Stocks for 5,000% Upside in 2024 and Beyond - Nasdaq

3 Top Penny Stocks for 5,000% Upside in 2024 and Beyond  Nasdaq

3 Top Penny Stocks for 5,000% Upside in 2024 and Beyond - Nasdaq

Click here to get full coverage on Kezar receives acquisition proposal from Concentra for $1.10 per share - Seeking Alpha

Kezar receives acquisition proposal from Concentra for $1.10 per share  Seeking Alpha

Kezar receives acquisition proposal from Concentra for $1.10 per share - Seeking Alpha

Click here to get full coverage on Kalamazoo anticipates Ashburton sale - Mining.com.au

Kalamazoo anticipates Ashburton sale  Mining.com.au

Kalamazoo anticipates Ashburton sale - Mining.com.au

Click here to get full coverage on Further boost to private enforcement of antitrust law - Noerr

Further boost to private enforcement of antitrust law  Noerr

Further boost to private enforcement of antitrust law - Noerr

Click here to get full coverage on Resources Top 5: Kalamazoo leads as Mallina West gold assays loom - Stockhead

Resources Top 5: Kalamazoo leads as Mallina West gold assays loom  Stockhead

Resources Top 5: Kalamazoo leads as Mallina West gold assays loom - Stockhead

Click here to get full coverage on KZR: Could it be a Gold Producer in 2017? - Next Investors

KZR: Could it be a Gold Producer in 2017?  Next Investors

KZR: Could it be a Gold Producer in 2017? - Next Investors

Click here to get full coverage on How Kino za Rogiem Reinvented the Neighbourhood Cinema - Celluloid Junkie

How Kino za Rogiem Reinvented the Neighbourhood Cinema  Celluloid Junkie

How Kino za Rogiem Reinvented the Neighbourhood Cinema - Celluloid Junkie

Click here to get full coverage on Kezar loses 41% of staff, CEO to keep lead lupus candidate on the road to phase 2 readout - Fierce Biotech

Kezar loses 41% of staff, CEO to keep lead lupus candidate on the road to phase 2 readout  Fierce Biotech

Kezar loses 41% of staff, CEO to keep lead lupus candidate on the road to phase 2 readout - Fierce Biotech

Click here to get full coverage on Kezar Life Sciences Announces Closing of Initial Public Offering and Exercise in Full of the Underwriters' Option to Purchase Additional Shares - PR Newswire

Kezar Life Sciences Announces Closing of Initial Public Offering and Exercise in Full of the Underwriters' Option to Purchase Additional Shares  PR Newswire

Kezar Life Sciences Announces Closing of Initial Public Offering and Exercise in Full of the Underwriters' Option to Purchase Additional Shares - PR Newswire

Click here to get full coverage on Interview with Bölzer vocalist and guitarist KzR - New Noise Magazine

Interview with Bölzer vocalist and guitarist KzR  New Noise Magazine

Interview with Bölzer vocalist and guitarist KzR - New Noise Magazine

Click here to get full coverage on Kalamazoo Resources Advances Mt Olympus Expansion with Underground Potential - Discovery Alert

Kalamazoo Resources Advances Mt Olympus Expansion with Underground Potential  Discovery Alert

Kalamazoo Resources Advances Mt Olympus Expansion with Underground Potential - Discovery Alert

Click here to get full coverage on Rebels Uncaged: The Kawasaki KZR-1 - motorcyclecruiser.com

Rebels Uncaged: The Kawasaki KZR-1  motorcyclecruiser.com

Rebels Uncaged: The Kawasaki KZR-1 - motorcyclecruiser.com

Click here to get full coverage on Kezar Life Sciences Announces Pricing of Initial Public Offering - PR Newswire

Kezar Life Sciences Announces Pricing of Initial Public Offering  PR Newswire

Kezar Life Sciences Announces Pricing of Initial Public Offering - PR Newswire

Click here to get full coverage on Small-cap players - KZR, IGE, FNT, QFY - Kalkine Media

Small-cap players - KZR, IGE, FNT, QFY  Kalkine Media

Small-cap players - KZR, IGE, FNT, QFY - Kalkine Media

Click here to get full coverage on Why this Peninsula startup is primed for an $80.5 million IPO - The Business Journals

Why this Peninsula startup is primed for an $80.5 million IPO  The Business Journals

Why this Peninsula startup is primed for an $80.5 million IPO - The Business Journals

Click here to get full coverage on Equities Analysts Set Expectations for KZR FY2025 Earnings - Defense World

Equities Analysts Set Expectations for KZR FY2025 Earnings  Defense World

Equities Analysts Set Expectations for KZR FY2025 Earnings - Defense World

Click here to get full coverage on Kezar Life Sciences (KZR) Expected to Announce Quarterly Earnings on Tuesday - Defense World

Kezar Life Sciences (KZR) Expected to Announce Quarterly Earnings on Tuesday  Defense World

Kezar Life Sciences (KZR) Expected to Announce Quarterly Earnings on Tuesday - Defense World

Click here to get full coverage on Kezar Life Sciences Stock Soars 40% After FDA Setback Sparks Strategic Shake-Up - ts2.tech

Kezar Life Sciences Stock Soars 40% After FDA Setback Sparks Strategic Shake-Up  ts2.tech

Kezar Life Sciences Stock Soars 40% After FDA Setback Sparks Strategic Shake-Up - ts2.tech

Click here to get full coverage on Brokerages Set Kezar Life Sciences, Inc. (NASDAQ:KZR) Target Price at $9.00 - Defense World

Brokerages Set Kezar Life Sciences, Inc. (NASDAQ:KZR) Target Price at $9.00  Defense World

Brokerages Set Kezar Life Sciences, Inc. (NASDAQ:KZR) Target Price at $9.00 - Defense World

Click here to get full coverage on Kezar Life Sciences (NASDAQ:KZR) Stock Rating Lowered by TD Cowen - Defense World

Kezar Life Sciences (NASDAQ:KZR) Stock Rating Lowered by TD Cowen  Defense World

KZR

Price Chart

Key Statistics

Technicals

About KZR

Latest News

KZR Embarks on Strategic Alternatives and Restructuring Plan - GuruFocus

All You Need to Know About Kezar Life Sciences (KZR) Rating Upgrade to Buy - Yahoo Finance

Kezar (NASDAQ: KZR) posts 36% remission in AIH at steroid doses ≤5 mg/day at AASLD - Stock Titan

Advanced Charts

Top Gainers

Top Losers